Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more ...

The pharmaceutical industry faces environmental challenges. Green chemistry offers sustainable solutions to reduce waste and enhance drug discovery processes.

Global drugmakers' stocks dropped across the board after US President Donald Trump reiterated plans for a "major" tariff on ...

The pharma sector was spared from Trump's sweeping tariff plan last week, which kicked in on Wednesday, but the U.S. president had previously pledged to impose tariff on pharma products and his ...

When a Pharma secures a new drug approval ... The market needs more certainty around what Merck’s drug product portfolio may look like in 2030, and how much revenue it is generating and what ...

In return, Hengrui Pharma will receive an upfront ... of these in-licensed drugs could help Merck reduce its dependence on a single product for growth. MRK’s deals with China are also a ...